Results
1 -
10 of
28Twelves C J, Gardner C, Flavin A, Sludden J, Dennis I, Bono J de, Beale P, Vasey P, Hutchison C, Macham M A, Rodriguez A, Judson I, Bleehen N M.
Phase I and pharmacokinetic study of DACA (XR5000): a novel inhibitor of topoisomerase I and II, British Journal of Cancer, 1999 The Role of PET Scanning in Determining Pharmacoselective Doses in Oncology Drug Development, Appropriate Dose Selection ? How to Optimize Clinical Drug Development Positron Emission Tomography Measurement of Drug Kinetics, In Vivo Imaging of Cancer Therapy Radiolabelled Anticancer Drugs for In vivo Pharmacokinetic Studies by PET, PET for Drug Development and Evaluation Experimental solid tumour activity ofN-[2-(dimethylamino)ethyl]-acridine-4-carboxamide, Cancer Chemotherapy and Pharmacology Pharmacokinetics of acridine-4-carboxamide in the rat, with extrapolation to humans, Cancer Chemotherapy and Pharmacology Pharmacokinetics and toxicity of the antitumour agentN-[2-(dimethylamino)ethyl]acridine-4-carboxamide after i.v. administration in the mouse, Cancer Chemotherapy and Pharmacology Tumour profile ofN-[2-(dimethylamino)ethyl]acridine-4-carboxamide after intraperitoneal administration in the mouse, Cancer Chemotherapy and Pharmacology Unusual dynamics of killing of cultured lewis lung cells by the DNA-intercalating antitumour agentN-[2-(dimethylamino)ethyl]acridine-4-carboxamide, Cancer Chemotherapy and Pharmacology Cytokinetic differences in the action ofN-[2-(dimethylamino)ethyl]acridine-4-carboxamide as compared with that of amsacrine and doxorubicin, Cancer Chemotherapy and Pharmacology